For decades, glaucoma treatment has followed one proven route: the trabecular pathway. But what if you’re only seeing half the picture?
Introducing AlloFlo™ Uveo from Iantrek, a new approach that activates the uveoscleral pathway, working with the eye’s natural design for powerful results:
- IOP reduction: 25.7 → 15.4 mmHg at 12 months (-40%)
- Medication reduction: 1.2 → 0.7 at 22 months (-42%)
- Validated by 3,000+ procedures
Join Dr. Glaucomflecken and the Iantrek team for the AlloFlo™ Uveo launch at AAO 2025:
- October 18 | 6:30–8:30 P.M.
- Ritz-Carlton Orlando, Grande Lakes
- Space is limited. Don’t miss out!
Plus, visit Iantrek Booth #3015 at AAO 2025 to learn more. The uveoscleral path awaits!
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
